CAPR R&D to Revenue
Capricor Therapeutics Inc · R&D to Revenue
CAPR R&D to Revenue
Latest reported0.00%period ending
CAPR Quarterly R&D/Revenue (0.00% → 0.00%)
Latest values, visible window
High-resolution chart · PNG
CAPR r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 130.7661% | |
| 522.0927% | |
| 314.8675% | |
| 226.2338% | |
| 82.2311% | |
| 162.1284% | |
| 225.0788% | |
| 256.5216% | |
| 649.2121% | |
| 345.8453% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 1,713.6617% | |
| 8,076.0535% | |
| 4,746.8511% | |
| 15,591.9291% | |
| 3,865.4601% | |
| 622.0784% | |
| 373.1423% | |
| 603.7573% | |
| 400.6307% | |
| 785.6697% | |
| 439.6049% | |
| 1,428.5128% | |
| 838.9444% | |
| 674.1388% | |
| 0% | |
| 594.3736% | |
| 313.9106% | |
| 369.7741% | |
| 389.997% | |
| 691.4913% | |
| 472.6493% | |
| 476.2699% | |
| 365.4584% | |
| 350.3178% | |
| 375.991% | |
| 365.3551% | |
| 184.3081% | |
| 188.7716% | |
| 178.119% | |
| 131.9578% | |
| 0.1251% | |
| 1,256.9624% | |
| 692.3118% | |
| 510.5212% | |
| -24.0327% | |
| 35.7353% | |
| 0% | |
| 238.0322% | |
| 686.445% | |
| 180.8118% | |
| 203.159% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 2,145.9566% | |
| 6,314.2303% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |